Vadadustat in Patients with Anemia and Non–Dialysis-Dependent CKD
Author(s) -
Glenn M. Chertow,
Pablo E. Pérgola,
Youssef M.K. Farag,
Rajiv Agarwal,
Susan Arnold,
Gabriel Bako,
Geoffrey A. Block,
Steven K. Burke,
Fausto P. Castillo,
Alan G. Jardine,
Zeeshan Khawaja,
Mark J. Koury,
Eldrin F. Lewis,
Tim Lin,
Wei Luo,
Bradley J. Maroni,
Kunihiro Matsushita,
Peter A. McCullough,
Patrick S. Parfrey,
Prabir RoyChaudhury,
Mark J. Sarnak,
Amit Sharma,
Bruce Spinowitz,
Carol Tseng,
James A. Tumlin,
Dennis Vargo,
Kimberly A. Walters,
Wolfgang C. Winkelmayer,
Janet Wittes,
KaiUwe Eckardt
Publication year - 2021
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa2035938
Subject(s) - anemia , dialysis , medicine , intensive care medicine
Vadadustat is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, a class of drugs that stabilize HIF and stimulate erythropoietin and red-cell production.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom